InMed Files Definitive Proxy for Mentari Reverse Merger: 98.99% Dilution, $490M Financing, Reverse Split
INM has more than doubled off its 52-week low of $0.575 on light trading volume (0.1× avg).
Summary
InMed's definitive proxy reveals existing shareholders will own just 1.01% of the combined company after the Mentari reverse merger, with a $490M pre-closing financing and reverse stock split to maintain Nasdaq listing.
Key Events · M&A and Partnerships · INM
-
Reverse Merger Ownership Split Quantified
InMed securityholders will own approximately 1.01% of the combined company post-merger (fully-diluted), with Mentari securityholders owning 98.99%. Exchange ratio is approximately 2.0056 InMed shares per Mentari share.
-
$490M Pre-Closing Financing
Mentari's pre-closing financing totals approximately $490 million (including $50M convertible notes), upsized from $290M in July 2026. Investors include Fairmount, Commodore Capital, Deep Track, Janus Henderson, a16z Bio + Health, and others.
-
Reverse Stock Split Required for Nasdaq
InMed must effect a reverse stock split (ratio range to be determined) to meet Nasdaq's $4.00 minimum bid price initial listing requirement. Without the split, the combined company cannot list on Nasdaq.
-
Going Concern and Liquidation Risk
Concurrent FY2026 10-K shows $2.2M cash runway into September 2026 and a going concern qualification. If the merger fails, InMed may pursue dissolution and liquidation with no assurance of shareholder distributions.
Analysis · INM · Life Sciences
This S-4/A is the definitive proxy statement for InMed's all-stock reverse merger with Mentari Therapeutics. The filing quantifies the deal for the first time: InMed shareholders will own just 1.01% of the combined company post-merger, with Mentari securityholders taking 98.99%. The exchange ratio is approximately 2.0056 InMed shares per Mentari share. The deal includes a $490 million pre-closing financing (upsized from $290M in July), a reverse stock split to meet Nasdaq's $4.00 minimum bid price, redomestication from British Columbia to Nevada, and a contingent value rights (CVR) agreement giving InMed shareholders potential future proceeds from legacy asset sales. InMed's FY2026 10-K filed concurrently shows a going concern qualification with only $2.2M cash — the merger is the primary path forward, and failure would likely lead to liquidation. The filing also details a new governance structure where Fairmount-affiliated Preferred Directors will control approximately 60% of board votes. This is a thesis-altering event for InMed shareholders: the company is effectively being acquired by Mentari, with existing holders retaining only a sliver of equity plus speculative CVR rights.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 49.5% of the 190 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.58 to $2.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.